ENO2 and lung carcinoma: As shown in Figure 2A and Table S1, there were significant differences in serum Cyfra21-1 (P = 0.003), CEA (P = 0.008), NSE (P = 0.036), and Pro-GRP (P = 0.006) levels among the benign lung disease and lung cancer.